Recruiting studies: Atypical Hemolytic Uremic Syndrome

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
Phase N/A · 7 location(s) · Alexion Pharmaceuticals, Inc. · NCT06312644 The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hospitals A Mu
Phase N/A · 8 location(s) · AstraZeneca · NCT07218536 Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS
Phase 3 · 9 location(s) · Novartis Pharmaceuticals · NCT05795140 Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypi
Phase 3 · 31 location(s) · Novartis Pharmaceuticals · NCT05935215 Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS
Phase 4 · 12 location(s) · Alexion Pharmaceuticals, Inc. · NCT07308574 Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy
NA · 1 location(s) · Mario Negri Institute for Pharmacological Research · NCT05805202 Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
Phase N/A · 141 location(s) · Alexion Pharmaceuticals, Inc. · NCT01522183 Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Phase N/A · 2 location(s) · Sanford Health · NCT01793168 Complement Prospective Evaluation of Thrombotic Microangiopathy on Endothelium
Phase N/A · 1 location(s) · Maastricht University Medical Center · NCT04745195 Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases
NA · 1 location(s) · Mario Negri Institute for Pharmacological Research · NCT05996731 Ravulizumab Outcomes in Polish Patients With aHUS
Phase N/A · 10 location(s) · AstraZeneca · NCT07399730 National Registry of Rare Kidney Diseases
Phase N/A · 1 location(s) · UK Kidney Association · NCT06065852 Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome
Phase 3 · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT05726916

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.